MinireviewEnzymes involved in the bioconversion of ester-based prodrugs
Section snippets
INTRODUCTION
An ideal drug candidate needs to have specific druglike properties, including chemical and enzymatic stability, solubility, low clearance by the liver or kidney, permeation across biological membranes, potency, and safety.1 In addition, drugs and drug formulations need to be “patient friendly,” that is, have minimal frequency of dosing (e.g., once daily), pleasant taste/odor if given orally, and minimal pain if given parenterally. Site-directed delivery of the drug to the target tissue/cell is
Esterases
The classification of esterases is complicated and confusing. While several classification systems exist, none appear to be totally satisfying and universally applied by investigators.
The International Union of Biochemistry and Molecular Biology (IUBMB) divides enzymes into six main categories according to the reactions they catalyze.19 Most enzymes involved in catalyzing the bioconversion of prodrugs belong to class 3–Hydrolyses; that is, carboxylesterases, which have the EC (Enzyme
FACTORS AFFECTING THE BIOCONVERSION OF ESTER PRODRUGS
In the case of prodrugs, the biotransformation in vivo to the active drug determines its ultimate usefulness since the prodrug itself has no pharmacological activity. The rate of biotransformation is particularly important because it plays an important role for the onset (e.g., immediate), duration (e.g., sustained release), and intensity of drug action. For prodrugs designed to increase solubility to promote parenteral use, such as phosphate prodrugs, rapid conversion in the blood is typically
SUMMARY AND CONCLUSION
An overview of the most significant factors and enzymes that dictate the stability of prodrugs in the body has been presented. While some of these factors, such as structural aspects of prodrugs, can be optimized in drug discovery, others are intrinsically related to individuals or certain populations, etc. As such, they create extra uncertainty and add to the complexity of any attempt to predict drug stability. While significant progress has been made in clarifying the mechanisms of how the
REFERENCES (163)
- et al.
Membrane transporter/receptor-targeted prodrug design: Strategies for human and veterinary drug development
Adv Drug Deliv Rev
(2004) Prodrug research: Futile or fertile?
Biochem Pharmacol
(2004)- et al.
Prodrug strategies to enhance the intestinal absorption of peptides
DDT
(1997) - et al.
Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human
J Pharm Sci
(2005) - et al.
Age- and gender-related differences in sensitivity to chlorpyrifos in the rat reflect developmental profiles of esterase activities
Toxicol Sci
(1998) - et al.
Esterases: Problems of identification and classification
Biochem Pharmacol
(1983) - et al.
Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model
Biochim Biophys Acta
(2004) - et al.
Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials
Chem Biol Interact
(1997) - et al.
Paraoxonase and coronary heart disease
Atheroscler Suppl
(2002) - et al.
The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity
Free Radic Biol Med
(2004)
Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role
Chem Biol Interact
Molecular aspects of carboxylesterase isoforms in comparison with other esterases
Toxicol Lett
Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: From binding promiscuity to selective inhibition
Chem Biol
Investigation of the role of a second conserved serine in carboxylesterases via site-directed mutagenesis
Arch Biochem Biophys
Covalent reaction intermediate revealed in crystal structure of the Geobacillus stearothermophilus carboxylesterase Est30
J Mol Biol
Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products
J Biol Chem
Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease
Prog Brain Res
Carboxylesterase-mediated transesterification of meperidine (Demerol) and methylphenidate (Ritalin) in the presence of [2H6]ethanol: Preliminary in vitro findings using a rat liver preparation
J Pharm Sci
Enzymes involved in the detoxification of organophosphorus, carbamate and pyrethroid insecticides through hydrolysis
Toxicol Lett
The beta-glucuronidase propeptide contains a serpin-related octamer necessary for complex formation with egasyn esterase and for retention within the endoplasmic reticulum
J Biol Chem
Two carboxylesterases bind C-reactive protein within the endoplasmic reticulum and regulate its secretion during the acute phase response
J Biol Chem
Synthesis, stereoselective enzymatic hydrolysis, and skin permeation of diastereomeric propranolol ester prodrugs
J Pharm Sci
Transport of acyclovir ester prodrugs through rabbit cornea and SIRC-rabbit corneal epithelial cell line
J Pharm Sci
Cefpodoxime-proxetil hydrolysis and food effects in the intestinal lumen before absorption: In vitro comparison of rabbit and human material
Int J Pharm
Acetylcholine esterase protects LDL against oxidation
Biochem Biophys Res Commun
Comparison of enzymatic hydrolysis of pilocarpine prodrugs in human plasma, rabbit cornea, and butyrylcholinesterase solutions
J Pharm Sci
Isosorbide-based aspirin prodrugs. II. Hydrolysis kinetics of isosorbide diaspirinate
Eur J Pharm Sci
Molecular and cellular biology of cholinesterases
Prog Neurobiol
Acetylcholinesterase: C-terminal domains, molecular forms and functional localization
J Physiol Paris
Molecular forms of acetylcholinesterase in brain, nerve and muscle: Nature, localization and dynamics
Prog Neurobiol
Identification of a human valacyclovirase: Biphenyl hydrolase-like protein as valacyclovir hydrolase
J Biol Chem
Rat liver paraoxonase: Subcellular distribution and characterization
Chem Biol Interact
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
Eur J Cancer
Biotechnology: Pharmaceutical aspects. Pharmaceutical profiling in drug discovery for lead selection
Targeted prodrug design to optimize drug delivery
AAPS PharmSci
Lessons learned from marketed and investigational prodrugs
J Med Chem
Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist
Curr Drug Metab
Enzyme-catalyzed activation of anticancer prodrugs
Pharmacol Rev
Prodrugs. Do they have advantages in clinical practice?
Drugs
Chemical aspects of selective toxicity
Nature
Clinical significance of esterases in man
Clin Pharmacokinet
Source book of enzymes
Prodrug approaches to the improved delivery of peptide drugs
Curr Pharm Des
Interindividual variation in carboxylesterase levels in human liver microsomes
Drug Metab Dispos
Pharmacogenetics of paraoxonases: A brief review
Naunyn Schmiedebergs Arch Pharmacol
Age dependency of esterase activity in rat and human keratinocytes
Biol Pharm Bull
Distinction between ‘A’-esterases and arylesterases. Implications for esterase classification
Biochem J
A new type of esterase in hog-kidney extract
Biochem J
Serum esterases
Biochem J
Cited by (307)
Drug and pro-drug substrates and pseudo-substrates of human butyrylcholinesterase
2023, Biochemical PharmacologyAutocatalytic strategy for tuning drug release from peptide-drug supramolecular hydrogel
2023, Chinese Chemical LettersAn endoplasmic reticulum-specific ratiometric fluorescent probe for imaging esterase in living cells
2023, Spectrochimica Acta - Part A: Molecular and Biomolecular SpectroscopyPredPS: Attention-based graph neural network for predicting stability of compounds in human plasma
2023, Computational and Structural Biotechnology JournalDevelopment of Prodrugs for Treatment of Parkinson‘s Disease: New Inorganic Scaffolds for Blood–Brain Barrier Permeation
2022, Journal of Pharmaceutical Sciences